Application of phenethyl lactam compound in preparation of medicine for preventing, treating or relieving interstitial cystitis
By using a combination of phenethyllactam compounds and other active ingredients, the problem of uncertain efficacy and major side effects of the treatment of interstitial cystitis in the prior art has been solved, and the effect of effectively improving bladder symptoms and reducing frequent urination is achieved.
Patent Information
- Application Number
- CN202411124722.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art has uncertain efficacy and great side effects in the treatment of interstitial cystitis, and lacks effective and safe drug solutions.
Phenethyllactam compounds are used, specifically 4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenethyl)pyridine-2(1H)-one or their pharmaceutically possible The accepted salt is used to prepare the prevention, treatment or alleviate interstitial cystitis, and combines other active ingredients such as tricyclic antidepressants, antihistamines, etc. to form a pharmaceutical composition.
Mice experiments showed that compounds can improve bladder edema, inflammatory cell infiltration, bleeding and mucosal destruction, reduce frequent urination and increase urination intervals, significantly improve the symptoms of interstitial cystitis, with accurate efficacy and fewer toxic side effects.
Smart Images

Figure BDA0004996805980000021 
Figure BDA0004996805980000051 
Figure BDA0004996805980000061
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to use of a phenethyl lactam compound in preparing a drug for preventing, treating or alleviating interstitial cystitis. Background Art
[0002] Interstitial cystitis (IC) is a chronic nonbacterial bladder inflammation, also known as bladder pain syndrome (BPS). The main clinical manifestations of this disease are long-term lower urinary tract irritation and pain symptoms, such as frequent urination, nocturia, urgency, increased urination, bladder oversensitivity, bladder discomfort, pelvic pain, etc., which seriously affect the quality of life of patients. According to cystoscopy, interstitial cystitis can be divided into ulcerative interstitial cystitis and non-ulcerous interstitial cystitis. At the same time, the diagnosis of interstitial cystitis requires the exclusion of many other diseases with similar symptoms, which is relatively difficult. The cause and pathogenesis of interstitial cystitis are unknown, and there are hypotheses such as occult infection and mast cell activation. Some symptoms of interstitial cystitis are similar to bacterial infection, but medical examinations show that there are no bacteria or viruses in the urine of patients with interstitial cystitis, and patients with interstitial cystitis do not respond to antibiotic treatment. Some people think that the occurrence of interstitial cystitis is due to ischemia or lack of a protein called glycosaminoglycan (GAG) in epithelial cells. Usually, a layer of GAG protein can protect the natural lining of the bladder (epithelium) from toxins in urine, but the lining of the bladder may be "leaky", causing substances in the urine to penetrate into the bladder wall, causing the bladder to become inflamed, soften, and unable to store urine well, which in turn causes symptoms of interstitial cystitis. Some people also think that interstitial cystitis is an autoimmune reaction after bladder infection. Therefore, the etiology and pathogenesis of interstitial cystitis are unknown, making it difficult to develop suitable drugs.
[0003] Currently, the treatment of interstitial cystitis is very limited, mainly oral tricyclic antidepressants, immunosuppressants, antihistamines, sodium polysulfate pentosan, etc., or intravesical drug instillation and surgical treatment such as cystoscopic electrocautery or ulcer resection to relieve symptoms, but the efficacy is still uncertain. For example, in a multicenter randomized controlled trial comparing oral hydroxyzine and sodium polysulfate pentosan for the treatment of IC, 121 patients were randomly divided and followed up for 18 months, and 79% of the patients completed the follow-up. Analysis of the results showed that there was no statistically significant difference in the therapeutic effect of the two drugs. Although antihistamines are recommended in some studies, the existing evidence is not sufficient to support their use as routine oral drugs for IC. Or the side effects are large, such as the adverse reactions of sodium polysulfate pentosan, including gastrointestinal reactions, fatigue, headache, etc., with an incidence of about 1%-80%. In addition, there have been more and more reports recently that sodium polysulfate pentosan may cause visual impairment, which limits the use of sodium polysulfate pentosan in IC.
[0004] Therefore, there is still a need to develop more effective and safer drugs for the treatment of interstitial cystitis. Summary of the invention
[0005] In view of this, the technical problem to be solved by the present invention is to provide a use of a phenethyl lactam compound in preparing a drug for preventing, treating or alleviating interstitial cystitis.
[0006] To achieve the above object, the present invention provides a use of a phenethyl lactam compound in the preparation of a drug for preventing, treating or alleviating interstitial cystitis;
[0007] The phenethyl lactam compound is 4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenethyl)pyridin-2(1H)-one or a pharmaceutically acceptable salt thereof.
[0008] The structural formula of the above 4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenethyl)pyridin-2(1H)-one is as follows:
[0009]
[0010] The pharmaceutically acceptable salts mentioned above may be inorganic acid salts or organic acid salts.
[0011] Preferably, the inorganic acid salt includes, but is not limited to, one or more of hydrochloride, sulfate, and phosphate.
[0012] Preferably, the organic acid salt includes, but is not limited to, one or more of acetate, sulfonate, malate, citrate, and tartrate.
[0013] The present invention has no particular limitation on the dosage form of the drug, including but not limited to oral dosage form or injection dosage form.
[0014] Preferably, the dosage form of the drug includes but is not limited to one or more of tablets, capsules, granules, oral liquids, suspensions, and powder injections.
[0015] The present invention shows through mouse experiments that the compound 4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenethyl)pyridin-2(1H)-one can improve bladder edema, inflammatory cell infiltration, bleeding and mucosal damage, reduce the time of licking the lower abdomen of model group mice, increase the single urine volume of mice, reduce urination frequency and increase the urination interval.
[0016] Based on this, the present invention provides a pharmaceutical composition for preventing, treating or alleviating interstitial cystitis, comprising 4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenethyl)pyridin-2(1H)-one or a pharmaceutically acceptable salt thereof.
[0017] Optionally, the above pharmaceutical composition further comprises other active ingredients for treating interstitial cystitis.
[0018] The above-mentioned other active ingredients preferably include, but are not limited to: one or more of tricyclic antidepressants, antihistamines, sodium pentosan, and pain medications.
[0019] Preferably, the tricyclic antidepressant is selected from amitriptyline.
[0020] Preferably, the antihistamine is selected from cimetidine or hydroxyzine.
[0021] Preferably, the pain treating drug is selected from cannabinoids or gabapentin.
[0022] The present invention has no particular limitation on the dosage form of the above-mentioned pharmaceutical composition, including but not limited to oral dosage form or injection dosage form.
[0023] Preferably, the dosage form of the pharmaceutical composition includes, but is not limited to, one or more of tablets, capsules, granules, oral liquids, suspensions, and powder injections.
[0024] Compared with the prior art, the present invention provides the use of a phenethyl lactam compound in the preparation of a drug for preventing, treating or alleviating interstitial cystitis; the phenethyl lactam compound is 4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenethyl)pyridin-2(1H)-one or a pharmaceutically acceptable salt thereof.
[0025] The present invention proves through experiments that the above-mentioned compounds can effectively improve bladder symptoms such as frequent urination, nocturia, urinary urgency, increased urination, bladder oversensitivity, and bladder discomfort, and has a definite therapeutic effect and few toxic and side effects, providing a new solution for the prevention and treatment of interstitial cystitis. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 The figure shows the histological changes in the rat model of interstitial cystitis induced by protamine sulfate and lipopolysaccharide;
[0027] Figure 2 This is a histological morphology diagram of the compound 1 of the present invention improving interstitial cystitis in rats;
[0028] Figure 3 This is a linear graph of the time of licking the lower abdomen of mice with cystitis induced by protamine sulfate and lipopolysaccharide as the compound 1 of the present invention;
[0029] Figure 4 is a bar graph of the single urine output of compound 1 of the present invention on rats with protamine sulfate and lipopolysaccharide-induced cystitis;
[0030] Figure 5The figure is a bar graph showing the effect of compound 1 of the present invention on the frequency of urination within 12 hours in rats with cystitis induced by protamine sulfate and lipopolysaccharide. DETAILED DESCRIPTION
[0031] In order to further illustrate the present invention, the use of the phenethyl lactam compound provided by the present invention in preparing a drug for preventing, treating or alleviating interstitial cystitis is described in detail below in conjunction with the examples. However, it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention, and are not intended to limit the claims of the invention.
[0032] All raw materials of the present invention are not particularly limited in their sources and can be purchased from the market or prepared according to conventional methods well known to those skilled in the art.
[0033] Example 1
[0034] Preparation of Compound 4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenethyl)pyridin-2(1H)-one
[0035] Place methyltriphenylphosphonium iodide (33.4g, 64mmol) and potassium tert-butoxide (9.3g, 64mmol) in a three-necked flask, add anhydrous THF (100mL), protect with argon, and react at room temperature for 1 hour. Dissolve 4-(difluoromethoxy)-3-(cyclopropylmethoxy)benzaldehyde (7.7g, 32mmol) in anhydrous THF (20mL) and slowly drip into the reaction solution through a constant pressure dropping funnel. After the addition is complete, react for 3 hours. Concentrate under reduced pressure to evaporate most of the THF, add saturated ammonium chloride solution (30mL) to quench the reaction, extract with ethyl acetate three times (3×50mL), combine the organic phases, wash the organic phase once with a saturated sodium chloride aqueous solution, separate the organic phase, and dry over anhydrous sodium sulfate. Medium pressure column chromatography separates the colorless transparent oil: 2-(cyclopropylmethoxy)-1-(difluoromethoxy)-4-vinylbenzene.
[0036] 2-(Cyclopropylmethoxy)-1-(difluoromethoxy)-4-vinylbenzene (1.1 g, 4.56 mmol), 1-benzyl-4-bromopyridin-2(1H)-one (1.2 g, 4.56 mmol), Pd 2 (dba) 3 (42mg, 0.0456mmol), HP(t-Bu) 3 BF 4(53mg, 0.1824mmol), DABCO (1.53g, 13.68mmol), add anhydrous dioxane (15mL), replace with argon, and tighten the stopper. React at 100℃ for 36 hours. After the reaction solution is cooled to room temperature, add saturated sodium bicarbonate aqueous solution (10mL) to quench the reaction. Extract with ethyl acetate three times (3×20mL), combine the organic phases, wash the organic phase once with saturated sodium chloride aqueous solution (20mL), separate the organic phase, and dry it over anhydrous sodium sulfate. Medium pressure column chromatography is used to separate the white solid (E)-1-benzyl-4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenylvinyl)pyridine-2(1H)-one.
[0037] Dissolve (E)-1-benzyl-4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenylvinyl)pyridin-2(1H)-one (70 mg, 0.17 mmol) in methanol (20 mL), add palladium carbon (20 mg), and react at 90°C for 5 h under a hydrogen atmosphere. Filter the palladium carbon through diatomaceous earth, wash the diatomaceous earth layer with ethyl acetate (2×10 mL), and combine the organic phases. Separate by medium pressure column chromatography to obtain a white solid, namely the following compound 1.
[0038]
[0039] Example 2
[0040] 1. Establishment of rat interstitial cystitis model induced by intravesical instillation of protamine sulfate and lipopolysaccharide
[0041] Female Sprague Dawley rats of 6-8 weeks old and sexually mature were selected, weighing 200-220g. The experimental rats were fed adaptively for 2 weeks, and the room was controlled with 12h light / 12h dark, temperature 20-26℃, humidity 50%-70%, and free access to food and water. The rats were randomly divided into two groups, 6 in each group. The rats in the experimental group were anesthetized by intraperitoneal injection of 10% chloral hydrate, and the urethral opening was disinfected with 70% ethanol and iodine tincture. A sterile catheter was inserted into the rat bladder through the urethra. After emptying the urine, 10mg / ml protamine sulfate was infused with 1ml, and retained for 45min. After the drug was exhausted, it was rinsed with phosphate buffer (PBS) and immediately infused with 1mL of 750μg / mL lipopolysaccharide, and retained for 30min. After 24h, the same method was repeated once, for a total of 3 times. The control group was infused with PBS in the same way. The rats were killed 4 weeks later, and the bladder tissue was collected for HE staining and mast cell staining. The histological morphology of rats with interstitial cystitis induced by protamine sulfate and lipopolysaccharide was changed. The lesions induced in the experimental group were composed of cell apoptosis, mucosal erosion, mucosal cell mitosis, mucosal hyperplasia, inflammatory cell infiltration and microhemorrhage. Figure 1 At the same time, the bladder tissue was observed under the microscope to evaluate the bladder edema and inflammatory cell infiltration. The results are shown in Table 1.
[0042] Table 1 Microscopic observation of bladder tissue in rats with interstitial cystitis
[0043]
[0044] On the basis of the above preliminary evaluation, 20 model rats were prepared with reference to the above modeling method, and the Von-Frey test was further used to determine whether the rat model of interstitial cystitis was successful. Each rat of the above modeling was placed individually in a transparent plastic test box with a grid floor and adapted for at least 10 minutes. Von Frey monofilament was applied 5 times in the lower abdominal area (close to the bladder) and 3 times on the plantar surface of both hind paws (to evaluate the reference pain), with the intensity from small to large, at intervals of 5 seconds, to determine the visceral sensitivity to mechanical stimulation. When the paw was sharply retracted, licking the paw occurred, or the animal retreated after the filament was removed, the stimulation-induced reaction was considered positive. The results showed that all 20 modeling rats were positive. Based on the above results, it was judged that the above method was successful in establishing the rat model of interstitial cystitis.
[0045] 2. Compound 1 is used to treat interstitial cystitis in rats
[0046] The interstitial cystitis rat model was divided into a 6 mg / mL experimental group and a model control group, with 10 rats in each group. A 6 mg / mL solution of compound 1 was administered orally to the experimental group once a day for 7 consecutive days. In addition, physiological saline was administered to the control group at the same time and volume. On the 8th day after administration, the rats were killed, and the bladder tissues were collected for HE staining to evaluate the therapeutic effect of compound 1 from a histological perspective. The results are shown in Figure 2. Figure 2 As shown, the left picture is the control group, and the right picture is the improvement of compound 1. Figure 2 It showed that compound 1 could improve bladder edema, inflammatory cell infiltration, bleeding and mucosal destruction.
[0047] 3. Compound 1 reduces the time of licking the lower abdomen in rat interstitial cystitis models induced by protamine sulfate and lipopolysaccharide
[0048] The interstitial cystitis rat model was prepared by the above method and divided into 3 mg / mL experimental group, 6 mg / mL experimental group, 10 mg / mL experimental group and model control group, with 10 rats in each group. 3 mg / mL, 6 mg / mL and 10 mg / mL solutions of compound 1 were administered to the experimental group by oral gavage once a day for 7 consecutive days. In addition, physiological saline was administered to the control group at the same time and volume. On the 8th, 9th and 10th day after administration, the behavior of mice was recorded for 90 minutes, and the time (seconds) for each animal in each group to lick the lower abdomen was calculated. The results are shown in Figure 3 As shown, Figure 3The results showed that compound 1 could reduce the time of licking the lower abdomen in the rat interstitial cystitis model induced by protamine sulfate and lipopolysaccharide.
[0049] 4. Compound 1 increases the single urine volume of rats with interstitial cystitis induced by protamine sulfate and lipopolysaccharide, and reduces the number of urinations within 12 hours
[0050] The interstitial cystitis rat model was prepared by the above method and divided into 3 mg / mL experimental group, 6 mg / mL experimental group, 10 mg / mL experimental group and model control group, with 10 rats in each group. 3 mg / mL, 6 mg / mL and 10 mg / mL solutions of compound 1 were administered to the experimental group by oral gavage once a day for 2 consecutive days. In addition, normal saline was administered to the control group at the same time and in the same volume. On the third day after administration, the intravesical pressure was measured by cystometry, and the urine volume of each rat was collected to calculate the single urine volume. The average value of each group was calculated based on the individual single urine volume and the number of urinations within 12 hours, and the results are shown in Figure 4 and Figure 5 The results showed that compound 1 could increase the single urination volume, reduce urinary frequency and increase the urination interval in rats with interstitial cystitis induced by protamine sulfate and lipopolysaccharide.
[0051] The above embodiments are only used to help understand the method and core idea of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. Use of phenethyl lactam compounds in the preparation of drugs for preventing, treating or alleviating interstitial cystitis; The phenethyl lactam compound is 4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenethyl)pyridin-2(1H)-one or a pharmaceutically acceptable salt thereof.
2. The use according to claim 1, characterized in that: The pharmaceutically acceptable salt is an inorganic acid salt or an organic acid salt.
3. The use according to claim 2, characterized in that: The inorganic acid salt includes one or more of hydrochloride, sulfate, and phosphate.
4. The use according to claim 2, characterized in that: The organic salt includes one or more of acetate, sulfonate, malate, citrate and tartrate.
5. The use according to claim 1, characterized in that: The dosage form of the drug is an oral dosage form or an injection dosage form.
6. The use according to claim 5, characterized in that: The dosage form of the drug is one or more of tablets, capsules, granules, oral liquids, suspensions, and powder injections.
7. A pharmaceutical composition for preventing, treating or alleviating interstitial cystitis, comprising 4-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenethyl)pyridin-2(1H)-one or a pharmaceutically acceptable salt thereof.
8. The pharmaceutical composition according to claim 7, characterized in that Other active ingredients for the treatment of interstitial cystitis are also included.
9. The pharmaceutical composition according to claim 8, characterized in that The other active ingredients include: one or more of tricyclic antidepressants, antihistamines, sodium pentosan, and pain medications.
10. The pharmaceutical composition according to claim 9, characterized in that The tricyclic antidepressant is selected from amitriptyline; The antihistamine is selected from cimetidine or hydroxyzine; The pain treatment drug is selected from cannabinoids or gabapentin.
